Critical treatment choices for patients with platinum-refractory urothelial carcinoma.

[1]  T. Powles,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[2]  V. Zagonel,et al.  Immunotherapy and urothelial carcinoma: An overview and future prospectives. , 2019, Critical reviews in oncology/hematology.

[3]  M. Höglund,et al.  Molecular pathology of the luminal class of urothelial tumors , 2019, The Journal of pathology.

[4]  R. Huddart,et al.  Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.

[5]  P. Hegde,et al.  Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial , 2018, The Lancet.

[6]  S. Culine,et al.  Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial , 2017, The Lancet.

[7]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[8]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[9]  M. Knowles,et al.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity , 2014, Nature Reviews Cancer.

[10]  M. Milowsky,et al.  Phase II study of sunitinib in patients with metastatic urothelial cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.